Progression of Geographic Atrophy with Subsequent Exudative Neovascular Disease in Age-Related Macular Degeneration

Written by: Mehnaz Khan, MD March 2021 Hwang CK, Agrón E, Domalpally A, Cukras CA, Wong WT, Chew EY, Keenan TDL; AREDS2 Research Group. Progression of Geographic Atrophy with Subsequent Exudative Neovascular Disease in Age-Related Macular Degeneration: AREDS2 Report 24. Ophthalmol Retina. 2021 Feb;5(2):108-117. doi: 10.1016/j.oret.2020.10.008. Epub 2020 Oct 16. PMID: 33075546; PMCID: PMC7870515. One […]

Cost Analysis of Routine Vitrectomy Surgery

Written by: Avni P. Finn, MD March 2021 Berkowitz S.T., Sternberg P., Jr & Patel S., Cost Analysis of Routine Vitrectomy Surgery, Ophthalmology Retina, Published February 11, 2021, DOI: https://doi.org/10.1016/j.oret.2021.02.003. Due to rising healthcare costs, value-based healthcare reform has been at the forefront of healthcare delivery and policy. In this model, healthcare is reimbursed according […]

Eplerenone for Chronic Central Serous Chorioretinopathy – (VICI): a Randomised, Double-blind, Placebo-Controlled Trial

Written by: Christian J. Sanfilippo, MD February 2021 Lotery, A., Sivaprasad, S., O’Connell, A., Harris, R. A., Culliford, L., Ellis, L., … Chakravarthy, U. (2020). Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. The Lancet, 395(10220), 294–303. doi:10.1016/s0140-6736(19)32981-2  Central serous chorioretinopathy […]

Outcomes of Combined Phacoemulsification and Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment: A Comparative Study

Written by: Jaya B. Kumar, MD February 2021 Tan A, Bertrand-Boiché M, Angioi-Duprez K, Berrod J, Conart J. Outcomes of Combined Phacoemulsification and Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment: A Comparative Study. Retina 2021; 41:68-74. For the majority of retina surgeons, pars plana vitrectomy (PPV) has become the preferred technique to repair primary rhegmatogenous […]

Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study

Written by: Wenlan (Wendy) Zhang, MD January 2021 Spooner KL, Fraser-Bell S, Cozzi M, Staurenghi G, Invernizzi A, Monteduro D, Munk MR, Hong T, Chang AA. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of […]

Factors Associated With the Use of 360-Degree Laser Retinopexy During Primary Vitrectomy With or Without Scleral Buckle for Rhegmatogenous Retinal Detachment and Impact on Surgical Outcomes

Written by: Andrew Tye, MD January 2021 Wang JC, Ryan EH, Ryan C, Kakulavarapu S, Mardis PJ, Rodriguez M, Stefater JA, Forbes NJ, Gupta O, Capone A Jr, Emerson GG, Joseph DP, Eliott D, Yonekawa Y; Primary Retinal Detachment Outcomes (PRO) Study Group. FACTORS ASSOCIATED WITH THE USE OF 360-DEGREE LASER RETINOPEXY DURING PRIMARY VITRECTOMY […]

Frequency of Rhegmatogenous Retinal Detachment after Intravitreal Therapy in Neovascular Age-Related Macular Degeneration

Written by: Priya Sharma Vakharia, MD Jan 2021 Mammo DA, Ringeisen AL, Parke DW. Frequency of rhegmatogenous retinal detachment after intravitreal therapy in neovascular age-related macular degeneration. Ophthalmology Retina 2020; 4:973-8. The purpose of this study was to look at patients who developed rhegmatogenous retinal detachment (RRD) within 90 days of intravitreal injection for neovascular […]